Royal Bank of Canada (RY): Just know that bank earnings are co...

Just know that bank earnings are coming out

nowwhat2 · 2022-01-05T19:26:56.2330000Z

Just know that bank earnings are coming out soon and that they're not gonna let THAT event pass without bullishness.... At some point in time - either before or after https://investorshub.advfn.com/uimage/uploads/2022/1/5/ophx[ry_a_5_8m_CPBFW_USPBFW_LOGO.jpg Deja vu....Shopify https://investorshub.advfn.com/uimage/uploads/2022/1/5/gfqapshop_a_4_HYPER_dwn_10pct.jpg Overhead "trend-Line" Repita por favor ! https://investorshub.advfn.com/uimage/uploads/2022/1/5/rbgiudjia_a_5_capture_djia_vs_nas.jpg

Play Episode

11min

Proactive - Interviews for investors

Immunic CMO discusses significance of MS Awareness Month; progress with treatment

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s work in multiple sclerosis (MS) as MS Awareness Month concludes. Muehler discussed the importance of continued research funding and the community’s role in advancing treatment. He highlighted the company’s lead asset, vidofludimus calcium, which is in advanced-stage clinical trials. Results from the phase 2 EMPHASIS trial in relapsing-remitting MS showed a reduction of about three-quarters of new MRI lesions compared to placebo. Muehler said, “This is a very good value,” and pointed to biomarker data showing a strong, dose-linear suppression of neurofilament — a sign of nerve cell damage. A phase 3 program involving more than 2,000 patients is now underway, with data expected in 2026. In progressive MS, Immunic is close to reporting data from its phase 2 CALLIPER trial, having already seen positive biomarker signals at 24 weeks. Muehler addressed patients’ fears of disability, stressing the company’s commitment to tackling "progression independent of relapse activity (PIRA)", a key unmet need. He emphasized vidofludimus calcium’s dual mechanism — both anti-inflammatory and neuroprotective — and its potential to become the first oral drug targeting the full spectrum of MS. To hear more insights from Immunic and other biotech leaders, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #ImmunicTherapeutics #MultipleSclerosis #MSAwarenessMonth #vidofludimuscalcium #MSTreatment #ClinicalTrials #Neuroprotection #MSResearch #BiotechNews #ProgressiveMS #RelapsingMS #PIRA #DrugDevelopment

Proactive - Interviews for investors

Andromeda Metals nears funding milestone for Great White Project

Andromeda Metals Ltd acting CEO Sarah Clarke talked with Proactive about the company's progress on its flagship Great White Project in South Australia. Clarke outlined how the company is nearing a critical funding milestone, having entered into exclusive negotiations with Merricks Capital for a debt financing facility of up to $75 million. She explained that this follows detailed due diligence and represents a significant advancement in the project’s development. She noted that the facility would cover capitalised interest, fees, and a cost overrun tranche, with exclusivity on negotiations running through to the end of July. Clarke also said Andromeda is pursuing the balance of required funds through a parallel equity or investment process. The Great White Project is a high-grade kaolin operation targeting premium ceramic markets and sustainable concrete products. The company has all key approvals in place, feasibility studies completed, long-lead items ordered, and binding offtake agreements secured for its Stage 1A+ development, which involves 100,000 tonnes of kaolin production per annum. Clarke said the project team is fully mobilised, working across both operational readiness and financing, to ensure rapid commencement of construction once funding is secured. Visit Proactive’s YouTube channel for more videos, and don’t forget to give the video a like, subscribe to the channel and enable notifications for future content. #AndromedaMetals #GreatWhiteProject #Kaolin #MiningAustralia #CriticalMinerals #CeramicsIndustry #GreenConcrete #ProjectFinancing #MerricksCapital #ProactiveInvestors

Proactive - Interviews for investors

Nextech3D.ai disrupts industry with launch of AI-powered Ecommerce content studio

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to announce the launch of a new AI-powered feature as part of the company’s Ecommerce AI Studio. The platform utilizes generative AI to create photorealistic lifestyle images and videos of products—such as apparel, accessories, and furniture—being worn, held, or displayed in realistic settings, eliminating the need for traditional photography. Gappelberg highlighted that ToggleStudios, Nextech3D.ai’s AI-driven content creation tool, is designed to help online retailers generate lifestyle content at scale. The platform reduces reliance on costly and time-consuming physical photoshoots, enabling faster content production, lower operating costs, and increased visual output. The new feature will allow users to generate AI-rendered images of apparel on virtual models with varied backgrounds and appearances. Additionally, retailers can visualize accessories, electronics, and other items in realistic usage scenarios, enhancing product presentation for e-commerce. Another major upgrade is the automated generation of product videos and interactive 3D visuals. Using advanced AI, the system simulates lighting, texture, and perspective, ensuring high-quality imagery that closely replicates traditional photography—but in less time and at a lower cost. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #AmazonSellerCentral #3DModeling #AIPhotography #EcommerceInnovation #3DTechnology #LifestylePhotography #ProactiveInterviews #TechInnovation #AmazonPartners#proactiveinvestors #nextech3d.al

Proactive - Interviews for investors

NanoViricides highlights broad-spectrum antiviral strategy and progress with lead drug candidate

NanoViricides Chief Financial Officer Meeta Vyas joined Steve Darling from Proactive to share updates on the company’s development of broad-spectrum antiviral therapeutics and its unique positioning amid global market uncertainty. Vyas emphasized that NanoViricides, headquartered in Shelton, Connecticut, conducts all of its research and development in-house, which insulates the company from international tariff fluctuations and supply chain disruptions. At the center of the company’s pipeline is NV-387, a broad-spectrum antiviral drug that differs from vaccines in both function and strategy. Rather than targeting specific viral strains, NV-387 works by mimicking the receptor sites used by over 90% of pathogenic viruses—including influenza, RSV, COVID-19, and smallpox. Vyas explained that this approach helps circumvent the problem of viral mutation, which often renders traditional vaccines less effective. “Regardless of how they mutate, they land on the same receptor site. So we copy the receptor site, which is invariant to mutation,” she said, underscoring the robustness of the NanoViricides platform. She also highlighted supportive regulatory developments in the U.S., noting that the new HHS administration has endorsed a more integrated approach to pandemic preparedness, which includes therapeutics like NV-387 as a key component. In light of recent USDA funding initiatives aimed at combating H5N1 avian flu, Vyas said the company is keen to explore applications of NV-387 in that space as well. Currently, NanoViricides is conducting a Phase 2 clinical trial targeting smallpox, following successful Phase 1 results with no reported adverse effects. #proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc NV387 #BroadSpectrumAntiviral #BiotechStocks #AntiviralTherapeutics #SmallpoxTreatment #BirdFlu #RSV #COVID19Treatment #ProactiveInvestors #PharmaInnovation #MeetaVyas #HHS #PandemicPreparedness

Followers	233
Posts	48708
Boards Moderated	10
Alias Born	02/07/2012

Volume:	2,030,202
Day Range:	106.10 - 112.11
Bid:
Ask:
Last Trade Time:	7:12:24 PM EDT
Total Trades:	30,500

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

RY Detailed Quote

Recent RY News

More RY News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent RY News

Go Ad-Free